Defined by the World Health Organization, « Essential medicines are those that satisfy the priority health care needs of the population (…) » (1)
Our injectable medicines allow the optimal management of patients, particularly in emergency and critical situations. For this reason, we make every effort to ensure the supply and safety of our products.
The problem of shortages in the supply of essential injectable drugs in hospitals is a complex challenge. The majority of shortages concern generic injectable drugs which are widely used in hospitals, particularly in operating theatres, emergency departments, intensive care and resuscitation. (2)
These shortages can have a significant impact on the ability of hospitals to treat patients. Aguettant makes every effort to remedy the shortcomings at the origin of the shortages:
- Ensure adequate production capacity
- Diversify the sources of supply of raw materials
- Anticipate regulatory approvals
- Improve inventory management
Pharmaceutical industrial sovereignty aims to strengthen a country's ability to produce its own medicines. This reduces import dependence and improves security of supply, economic independence, quality control and the ability to innovate. Aguettant is proud to be part of the France Relance plan since 2020.